38
Participants
Start Date
September 17, 2007
Primary Completion Date
August 1, 2016
Study Completion Date
December 1, 2017
Dasatinib
"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
Dasatinib Maximum Tolerated Dose
An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
University of Nebraska Medical Center, Internal Medicine Section of Oncology/Hematology, Omaha
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
University of Nebraska
OTHER